Expert Highlights Applications of Proton Therapy in Radiation Oncology

Commentary
Video

The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.

Administering proton therapy to pediatric populations with cancer may serve as a “great application” that helps patients avoid developing mutations and second cancers, says Timothy Chen, MD.

Chen, a board-certified radiation oncologist and medical director of the Central Nervous System Program at Jersey Shore University Medical Center and the director of Proton Therapy in the Department of Radiation Oncology at Hackensack Meridian Health, spoke with CancerNetwork® about the potential applications of proton therapy and benefits this modality may offer compared with standard radiation.

In addition to the potential utility of proton therapy among pediatric populations, Chen highlighted how this technique may demonstrate more precision than others based on what he described as a “depth charge.” For example, it may be possible to administer proton therapy to breast tumors while sparing the lungs from receiving any excess radiation.

Transcript:

Proton therapy is type of radiation but with a different particle hitting the target. If you think about conventional radiation like a pistol, proton [therapy] is like a cannon. It also has a great purpose with what’s called a depth charge. We can set a cannon to be explored at a certain depth. The conventional radiation comes and goes while passing through the structure. With proton therapy, we can say where I want to go and stop right there. With that, there are great applications.

No. 1 is in pediatric [patients with] cancer. Because a child is still growing, the conventional radiation can create mutations, and they could eventually develop a second cancer in their later life. Proton therapy is a particularly great design for pediatric patients [with] cancer; their chance of getting a mutation or a second cancer is smaller.

The second thing is about the depth charge. Because we can set the characteristic of this beam, we can treat quite a large area that’s not accessible with conventional radiation. For example, in breast cancer, the breast sits on top of the chest wall, and as we breathe, the lungs get in [the way and receive] the radiation. But because we can set the depth [with proton therapy], you can confine radiation to the breasts and not touch the lungs.

Recent Videos
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
Related Content